RxDoctor Payments Data

Christina Paruthi, MD

Cardiovascular Disease · Houston, TXNPI 1598070799

Payments from drug & device makers

$1,826in general payments, 2019–2025

Across 31 payments — averaging $58.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$549
  • Johnson & Johnson$284
  • Edwards Lifesciences$257
  • Impulse Dynamics (USA) Inc.$169
  • Esperion Therapeutics, Inc.$122
  • Intuitive Surgical$77
  • plus $368 from 12 others

What the payments were for

  • Food & beverage$1,77397%
  • Education$523%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,826 in reported general payments places this provider in the 30th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$138,627
Medicare patients
351
Services billed
1,167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban183$216,443
MounjaroTirzepatide120$150,637
EntrestoSacubitril/Valsartan75$111,331
OzempicSemaglutide42$45,101
Repatha SureclickEvolocumab31$37,206
WegovySemaglutide20$29,212
XareltoRivaroxaban31$22,548
Repatha SyringeEvolocumab15$18,384
KerendiaFinerenone17$15,354
Metoprolol Succinate237$4,088
Diltiazem 24hr Er (La)Diltiazem Hcl41$2,851
Atorvastatin Calcium333$2,759
Ranolazine ErRanolazine15$2,362
Carvedilol182$2,070
Rosuvastatin Calcium112$1,934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$41$150,637120 claims
Novo NordiskOzempic, Wegovy$32$74,31362 claims
Johnson & JohnsonXarelto$284$22,54831 claims
BayerKerendia$20$15,35417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →